Tags

Type your tag names separated by a space and hit enter

Dengue vaccines approach the finish line.
Clin Infect Dis. 2007 Jul 15; 45 Suppl 1:S56-60.CI

Abstract

The spread of dengue virus (DV) via its Aedes mosquito vector throughout most of the tropics has led to a worldwide resurgence of epidemic dengue, including dengue hemorrhagic fever. For the first time in 60 years, the pipeline of dengue vaccines looks promising. Strains of each of the 4 DV serotypes, attenuated by passage in tissue culture or by recombinant DNA technology, have been formulated into tetravalent vaccines and have entered successful phase 1 and 2 clinical trials in the United States and Southeast Asia. Antibody-dependent enhancement of wild-type DV infections by the vaccine represents a unique safety issue, which is under investigation. The Pediatric Dengue Vaccine Initiative (funded by the Bill and Melinda Gates Foundation), the World Health Organization, industry, the US military, and governments of tropical countries are collaborating to accelerate dengue vaccine development and phase 3 vaccine efficacy trials in countries where dengue is endemic. A protective tetravalent vaccine must be licensed soon if dengue is to be brought under control.

Authors+Show Affiliations

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA. redelman@medicine.umaryland.edu

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17582571

Citation

Edelman, Robert. "Dengue Vaccines Approach the Finish Line." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 45 Suppl 1, 2007, pp. S56-60.
Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis. 2007;45 Suppl 1:S56-60.
Edelman, R. (2007). Dengue vaccines approach the finish line. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 45 Suppl 1, S56-60.
Edelman R. Dengue Vaccines Approach the Finish Line. Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S56-60. PubMed PMID: 17582571.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dengue vaccines approach the finish line. A1 - Edelman,Robert, PY - 2007/7/14/pubmed PY - 2007/8/19/medline PY - 2007/7/14/entrez SP - S56 EP - 60 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 45 Suppl 1 N2 - The spread of dengue virus (DV) via its Aedes mosquito vector throughout most of the tropics has led to a worldwide resurgence of epidemic dengue, including dengue hemorrhagic fever. For the first time in 60 years, the pipeline of dengue vaccines looks promising. Strains of each of the 4 DV serotypes, attenuated by passage in tissue culture or by recombinant DNA technology, have been formulated into tetravalent vaccines and have entered successful phase 1 and 2 clinical trials in the United States and Southeast Asia. Antibody-dependent enhancement of wild-type DV infections by the vaccine represents a unique safety issue, which is under investigation. The Pediatric Dengue Vaccine Initiative (funded by the Bill and Melinda Gates Foundation), the World Health Organization, industry, the US military, and governments of tropical countries are collaborating to accelerate dengue vaccine development and phase 3 vaccine efficacy trials in countries where dengue is endemic. A protective tetravalent vaccine must be licensed soon if dengue is to be brought under control. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/17582571/Dengue_vaccines_approach_the_finish_line_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/518148 DB - PRIME DP - Unbound Medicine ER -